ReviewFrontiers in endocrinology2023
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Peripheral nerve complications from medications utilised for weight loss: a systematic review.Journal of neurology · 2026Pooled it
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) · 2026Trial
- Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?Diagnostics (Basel, Switzerland) · 2026Article
- Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis.Internal and emergency medicine · 2026Review
- Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity.Stigma and health · 2026Article
- Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.Obesity pillars · 2026Review
- Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.Therapeutic advances in endocrinology and metabolism · 2026Review
- Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.World journal of diabetes · 2025Article
- GLP-1 agonists: a game changer in pain treatment and addiction.Pain management · 2025Review
- Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP-1R/GIPR dual agonist, HISHS-2001.Diabetes, obesity & metabolism · 2025Article
- Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.Diabetes, obesity & metabolism · 2025Article
- The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells.Cardiovascular diabetology · 2025Article
- Obesity- and diet-induced plasticity in systems that control eating and energy balance.Obesity (Silver Spring, Md.) · 2024Review
- Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.Journal of diabetes and metabolic disorders · 2024Article
- Beyond pounds: What else could be lost?Journal of diabetes and its complications · 2023Article
- Emerging Anesthesia Risks with Semaglutide.Plastic and reconstructive surgery. Global open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of obesity is an increasing issue worldwide, especially in industrialized countries. Weight loss is important both to treat obesity and to prevent the development of complications. Currently, several drugs are used to treat obesity, but their efficacy is modest. Thus, new anti-obesity treatments are needed. Recently, there has been increased interest in the development of incretins that combine body-weight-lowering and glucose-lowering effects. Therefore, a new drug that simultaneously coactivates both the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) has been developed. Tirzepatide, the first in this class, improves glycemic control by increasing insulin sensitivity and lipid metabolism as well as by reducing body weight. Combining the activation of the two receptors, greater improvement of β-cell function offers more effective treatment of diabetes and obesity with fewer adverse effects than selective GLP-1R agonists. In the present review, we discuss the progress in the use of GIPR and GLP-1R coagonists and review literature from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.